About Putative transporter SVOPL
Putative transporter SVOPL (SVOPL) is a protein
from Homo sapiens identified by UniProt accession
Q8N434, 492 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | Putative transporter SVOPL |
|---|
| UniProt accession | Q8N434 |
|---|
| Gene | SVOPL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 492 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (18)
Diseases linked to this target (Open Targets).
- IGF-1 measurement · score 0.21
- protein measurement · score 0.16
- Non-immune hydrops fetalis · score 0.11
- ulcerative colitis · score 0.02
- neoplasm · score 0.01
- COVID-19 · score 0.01
- Intestinal epithelial dysplasia · score 0.01
- melanoma · score 0.01
- lung carcinoma · score 0.01
- insulin resistance · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8N434-F1 | alphafold | PREDICTED | 83.84 | — |
Amino-acid sequence (492 residues)
MATKPTEPVT ILSLRKLSLG TAEPQVKEPK TFTVEDAVET IGFGRFHIAL FLIMGSTGVV EAMEIMLIAV VSPVIRCEWQ LENWQVALVT TMVFFGYMVF SILFGLLADR YGRWKILLIS FLWGAYFSLL TSFAPSYIWF VFLRTMVGCG VSGHSQGLII KTEFLPTKYR GYMLPLSQVF WLAGSLLIIG LASVIIPTIG WRWLIRVASI PGIILIVAFK FIPESARFNV STGNTRAALA TLERVAKMNR SVMPEGKLVE PVLEKRGRFA DLLDAKYLRT TLQIWVIWLG ISFAYYGVIL ASAELLERDL VCGSKSDSAV VVTGGDSGES QSPCYCHMFA PSDYRTMIIS TIGEIALNPL NILGINFLGR RLSLSITMGC TALFFLLLNI CTSSAGLIGF LFMLRALVAA NFNTVYIYTA EVYPTTMRAL GMGTSGSLCR IGAMVAPFIS QVLMSASILG ALCLFSSVCV VCAISAFTLP IETKGRALQQ IK
Explore Putative transporter SVOPL with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets